Core Viewpoint - Huayi Taikang Pharmaceutical Co., Ltd. is progressing with its IPO guidance, with the guidance period set from April 1, 2025, to June 30, 2025, after starting the IPO filing on January 26, 2024 [2] Company Overview - Huayi Taikang was established in June 2010, focusing on the research, development, production, and sales of complex formulations and innovative formulations, providing one-stop, international pharmaceutical R&D and customized production services [3] - The company has a registered capital of 60.048 million yuan and is legally represented by Zhu Honggang [3] Product Portfolio - The main products approved for sale include sustained-release metoprolol succinate tablets, enteric-coated paroxetine sustained-release tablets, tacrolimus capsules, enteric-coated esomeprazole magnesium capsules, and agomelatine tablets, primarily used in treating hypertension, depression, organ transplantation, digestive system, and neurological diseases [4] Financial Performance - Revenue for Huayi Taikang from 2022 to 2024 was 113 million yuan, 258 million yuan, and 308 million yuan respectively, with net profits of -40.59 million yuan, 65.64 million yuan, and 59.40 million yuan [5] - In Q1 2025, the company reported revenue of 85.24 million yuan, a year-on-year increase of 30.41%, and a net profit of 28.46 million yuan, a year-on-year increase of 175.71% [6][8] - The basic earnings per share for Q1 2025 was 0.47 yuan, compared to 0.18 yuan in the same period last year [8]

Group 1 - Huayi Taikang Pharmaceutical Co., Ltd. (Huayi Taikang) has initiated its IPO counseling process, with the counseling period set from April 1, 2025, to June 30, 2025 [3] - The counseling includes all directors, supervisors, senior management, and shareholders holding more than 5% of the shares [3] - The company has appointed Wang Jin as a new director during the counseling period [3] Group 2 - Established in June 2010, Huayi Taikang focuses on the research, production, and sales of complex and innovative formulations, providing one-stop international pharmaceutical R&D and customized production services [4] - The company has received approval for several key products, including Succinic Acid Metoprolol Sustained-Release Tablets and Tacrolimus Capsules, which are primarily used in treating hypertension, depression, organ transplants, and digestive and neurological diseases [4] - Revenue figures for Huayi Taikang from 2022 to 2024 are 113 million, 258 million, and 308 million yuan, respectively, with net profits of -40.59 million, 65.64 million, and 59.40 million yuan [4] Group 3 - In the first quarter of 2025, Huayi Taikang reported revenue of 85.24 million yuan, a year-on-year increase of 30.41%, and a net profit of 28.46 million yuan, up 175.71% [5] - The company’s basic earnings per share for the first quarter of 2025 is 0.47 yuan, compared to 0.18 yuan in the same period last year [6] - The weighted average return on equity based on net profit attributable to shareholders for the first quarter of 2025 is 7.31%, up from 4.69% in the previous year [6] Group 4 - Zhu Honggang is the controlling shareholder and actual controller of Huayi Taikang, holding a direct stake of 1.58% and controlling a total of 36.78% of the voting rights through various entities [6] - Zhu Honggang has a background in pharmaceutical sciences, holding a Ph.D. from the University of Utah, and has held various managerial positions in the pharmaceutical industry since 2003 [8]